Elevance Health is a publicly traded company in the Healthcare sector. Operating in the heavily regulated healthcare industry, this company is significantly impacted by Medicare/Medicaid policy changes, FDA regulatory decisions, and pharmaceutical pricing legislation. HillSignal is tracking 9 active Congressional signals mentioning Elevance Health, including 9 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
The OPTIONS Act (HR8314) is a procedural early-stage bill referred to committee with zero near-term market impact. Directionally, it accelerates the structural tailwind for HSA/HRA adoption over traditional fully-insured group plans, creating a multi-year headwind for commercial health insurers. The bill has no appropriated funding, no spending authorization, and faces a long and uncertain legislative path through the 119th Congress.
→ Accelerates secular shift from fully-insured group medical plans to defined-contribution HSA/HRA arrangements, reducing enrollment in traditional commercial group risk pools over a multi-year horizon.
HR6837 is an early-stage House bill imposing ERISA fiduciary duty on pharmacy benefit managers, directly threatening the lucrative rebate retention and spread pricing revenue model for CVS, CI, ELV, UNH, and HUM. Despite the bearish structural impact, the market has priced in a 16–36% rally across these tickers over the past 30 days, reflecting broad skepticism that the bill will pass in its current form. With no companion Senate markup and bipartisan momentum limited (one R cosponsor), passage is a 30–40% probability over the next 12 months. Long-term risk for PBM margins is real but deferred.
→ Carelon must eliminate spread pricing and rebate retention; approximately 15% of Carelon revenue comes from prescription drug claims processing, and ~30–40% of that segment's margin is from spread/rebate arbitrage. Total Carelon revenue was ~$75B in FY2024; margin impact estimated at $500M–$900M.
HR2148, the Veteran Caregiver Reeducation, Reemployment, and Retirement Act, expands VA medical coverage for family caregivers and creates a transition pipeline into Medicare Advantage. The bill is out of committee and awaiting House floor action with a Senate companion bill (S879) also advancing. Major health insurers (HUM, UNH, ELV, CVS, CI) have rallied 3.7%–12.66% in the past week and 8.8%–39.85% over 30 days on sector momentum partially attributed to this legislative catalyst and related executive actions. The bill does not authorize specific dollar amounts but expands an existing VA program, creating incremental MA enrollment opportunities estimated at 5,000–15,000 lives annually.
→ Incremental MA membership from caregiver pipeline; Elevance has ~4.5 million MA members and strong state-level VA relationships. Caregiver transitions represent a very small (0.05–0.1%) but incremental MA growth driver.
The Improving Seniors' Timely Access to Care Act mandates electronic prior authorization for all Medicare Advantage plans by 2028, forcing a regulatory-driven health IT spending wave. Oracle (ORCL) is the clearest beneficiary as dominant EHR vendor, while major MA insurers (UNH, ELV, HUM, CVS) face mandated IT investment but gain long-term operational efficiency. The bill has strong bipartisan momentum with 68 cosponsors and an identical House companion.
→ ELV must invest in IT upgrades for e-prior authorization compliance, incurring short-term costs with long-term operational savings
The Medicare Advantage Prompt Pay Act (HR5454) is early-stage legislation that would mandate MA plans to pay 95% of clean claims within 14 days (electronic in-network) or 30 days (other). This eliminates float income and increases administrative costs for MA insurers. Recent rallies in UNH (+3.3% 7-day), HUM (+12.12%), ELV (+8.12%), MOH (+10.8%), and CVS (+6.9%) appear disconnected from this structural headwind.
→ Accelerated claims payment for MA book but ELV is more diversified across Commercial, Medicaid, and ACA than HUM. MA represents ~25-30% of total revenue.
HR6609 is an early-stage bill that would mandate rebate pass-throughs and ban patient steering by PBMs in Medicare and Medicaid. The bill has 36 cosponsors but remains in committee since December 2025 with no further action — legislative probability is low near-term. Despite real headwinds for CVS, CI, UNH, and ELV, the market has rallied these names 3-10% in the past week and 8-42% in 30 days on unrelated earnings and sector rotation, not this bill.
→ Elevance's health plan subsidiaries (Anthem BCBS) and any associated PBM arrangements would face rebate pass-through and anti-steering requirements on government business.
HR7861 (Care Over Profits Act) proposes raising the minimum MLR from 80% to 85% for individual/small group health plans. The bill is early-stage, referred to committee, and faces long odds, with only one cosponsor and no companion in the Senate. Despite the bearish direct impact on insurer margins, major health insurer stocks have rallied 7-40% over the past 30 days, indicating the market is not pricing in legislative risk.
→ Insurers must spend at least 85% of premium dollars on medical claims/quality improvement, reducing the maximum allowable administrative overhead and profit margin from 20% to 15% of premiums. For every $100 in premium revenue, the maximum retained for non-medical costs drops from $20 to $15.
The No Surprises Act Enforcement Act (HR4710) is an early-stage House bill that would increase balance billing penalties from $100/day to $10,000 per violation for health insurers. The bill has been referred to three committees and has a Senate companion (S2420). Despite the bearish legislative signal, major insurers including ELV (+7.71% 7-day) and HUM (+13.29% 7-day) have shown strong recent price momentum driven by other factors.
→ Maximum penalty per violation rises from $100 per day to $10,000 per failure, representing a 100x increase in per-incident liability
HR6364 (Kidd's Stuttering Act) mandates Medicaid and CHIP coverage for childhood stuttering screening and speech therapy, creating a new, guaranteed revenue stream for managed care organizations and speech therapy providers. The bill is in early stage (referred to committee) with 12 cosponsors. Real market data shows UNH, ELV, and HUM all up 32-46% in the last 30 days, though this is likely driven by broader sector momentum rather than this specific bill at this stage.
→ Creates a guaranteed increase in covered service volume for speech therapy and diagnostic screenings for children aged 2-5 enrolled in Medicaid/CHIP. Capitation payments will be adjusted upward by CMS to cover the new mandated services.